Enumera Molecular Overview
- Year Founded
-
2022
- Status
-
Private
- Employees
-
16
- Latest Deal Type
-
Series B
- Latest Deal Amount
-
$12.3M
- Investors
-
2
Enumera Molecular General Information
Description
Developer of a biomolecule assessment platform designed to offer clinical diagnostics. The company's platform offers a variety of tests designed to fit clinical lab settings across application areas such as oncology, reproductive health, transplant, pharmacogenomics, and infectious disease testing, enabling physicians to get low-cost systems for rapid clinical liquid biopsy tests.
Contact Information
Website
www.enumeramolecular.comCorporate Office
- 600 South Wagner Road
- Ann Arbor, MI 48103
- United States
Corporate Office
- 600 South Wagner Road
- Ann Arbor, MI 48103
- United States
Enumera Molecular Timeline
Enumera Molecular Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Early Stage VC (Series B) | 30-Jul-2026 | $12.3M | Completed | Generating Revenue | ||
| 1. Early Stage VC (Series A) | 16-Aug-2022 | Completed | Generating Revenue |
Enumera Molecular Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A | ||||||||
| Series A1 |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Enumera Molecular Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Enumera Molecular Patents
Enumera Molecular Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026161458-A1 | Methods and compositions for background reduction in nucleic acid detection | Pending | 21-Jan-2025 | ||
| WO-2026152127-A1 | Methods, systems, and compositions relating to boronic acid-treated surfaces | Pending | 13-Jan-2025 | ||
| US-20240301492-A1 | Methods of preparing assays, systems, and compositions for determining fetal fraction | Pending | 24-Dec-2020 | ||
| JP-2024504247-A | Method and system for image processing | Active | 11-Dec-2020 | ||
| AU-2021397238-A1 | Methods and systems for image processing | Pending | 11-Dec-2020 | G06T7/194 |
Enumera Molecular Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Enumera Molecular Investors (2)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Arboretum Ventures | Venture Capital | Minority | ||
| Biora Therapeutics | Corporation | Minority |
Enumera Molecular Investments (1)
Enumera Molecular’s most recent deal was a Corporate Asset Purchase with Biora Therapeutics (Liquid Biopsy Technologies in San Diego, California). The deal was made on 05-May-2022.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Biora Therapeutics (Liquid Biopsy Technologies in San Diego, California) | 05-May-2022 | Corporate Asset Purchase | Buildings and Property |
Enumera Molecular FAQs
-
When was Enumera Molecular founded?
Enumera Molecular was founded in 2022.
-
Where is Enumera Molecular headquartered?
Enumera Molecular is headquartered in Ann Arbor, MI.
-
What is the size of Enumera Molecular?
Enumera Molecular has 16 total employees.
-
What industry is Enumera Molecular in?
Enumera Molecular’s primary industry is Decision/Risk Analysis.
-
Is Enumera Molecular a private or public company?
Enumera Molecular is a Private company.
-
What is Enumera Molecular’s current revenue?
The current revenue for Enumera Molecular is .
-
How much funding has Enumera Molecular raised over time?
Enumera Molecular has raised $31.2M.
-
Who are Enumera Molecular’s investors?
Arboretum Ventures and Biora Therapeutics have invested in Enumera Molecular.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
